RxDoctor Payments Data

John Godfrey, DO

Cardiovascular Disease · Springfield, PANPI 1770704850

Payments from drug & device makers

$1,618in general payments, 2019–2025

Across 76 payments — averaging $21.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$245
  • Pfizer$239
  • Novartis$225
  • Abbott$172
  • Kiniksa Pharmaceuticals International, PLC$135
  • Johnson & Johnson$106
  • plus $496 from 12 others

What the payments were for

  • Food & beverage$1,59999%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,618 in reported general payments places this provider in the 45th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$917,478
Medicare patients
1,957
Services billed
5,775

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban315$281,389
EntrestoSacubitril/Valsartan202$209,398
XareltoRivaroxaban134$120,344
Repatha SureclickEvolocumab49$37,402
JardianceEmpagliflozin17$16,334
BrilintaTicagrelor13$12,969
Praluent PenAlirocumab13$8,464
Atorvastatin Calcium641$7,167
Metoprolol Succinate472$6,094
Ezetimibe243$5,797
LumiganBimatoprost19$4,656
Diltiazem 24hr Er (Cd)Diltiazem Hcl113$4,121
Flecainide Acetate64$4,110
Rosuvastatin Calcium203$3,327
Carvedilol227$1,949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$239$281,389315 claims
NovartisEntresto$225$209,398202 claims
Johnson & JohnsonXarelto$106$120,344134 claims
Boehringer IngelheimJardiance$72$16,33417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Springfield

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →